Last updated: July 27, 2026
What clinical trials have been reported for Lysteda (tranexamic acid) since 2020?
No Lysteda-specific phase-advancing trials or new registrational programs were identified in the available sources used for this analysis. Public disclosures continue to emphasize established use for heavy menstrual bleeding (HMB) from prior approvals, with ongoing activity largely limited to post-marketing, observational, and non-registrational studies.
What is the current evidence base behind Lysteda’s US indication for HMB?
Lysteda is approved for treatment of cyclic heavy menstrual bleeding in women who do not have contraindications to tranexamic acid. The core clinical package derives from earlier randomized trials that established efficacy versus placebo and supportive safety characterization, including thromboembolic risk assessment.
Are there notable trials targeting new delivery forms, dosing, or combination regimens?
From the available source set used here, no new, publicly disclosed, phase-III registrational-stage programs for Lysteda (tranexamic acid tablets) were identified that would change label scope, dosing schedule, or patient segmentation.
What is the FDA status of Lysteda for heavy menstrual bleeding and how does exclusivity look?
Lysteda’s FDA approval is established; exclusivity has run its course. The product is not tied to current biologics-style exclusivity and functions as a small-molecule branded drug where generic and authorized products compete.
Is Lysteda still protected from generic substitution via patent or exclusivity barriers?
Exclusivity barriers are not determinative for Lysteda in the current market. The practical barrier remains patent coverage on specific claims (formulation, methods, or combinations) and Orange Book listings, which is consistent with a mature small-molecule market structure where generics often enter when listed patents expire or are cleared.
Orange Book status
Orange Book listing status is not reproduced here because the required patent list and expiration dates are not included in the provided source set for this run.
Who sells Lysteda today and what is the competitive landscape versus generic tranexamic acid?
Lysteda competes against generic tranexamic acid tablets for HMB. Market dynamics are shaped by pharmacy benefit manager contracting, wholesale pricing, and payor preference for lower net-cost equivalents.
How does the competitive product set typically map?
- Branded originator: Lysteda (tranexamic acid tablets).
- Generic tranexamic acid: Multiple ANDA products from various manufacturers in the US.
- Authorized alternatives by channel: Rebates, pack size offerings, and contracting strategies determine share more than clinical differentiation.
What pricing and contracting factors drive market share?
- Net price after rebates and dispensing fees
- Patient out-of-pocket costs under formularies
- Pharmacy acquisition costs and turnover
- Step-edit or prior authorization policies in some payor plans
How big is the Lysteda market and what share does it typically command?
A precise current-year US share for Lysteda versus generics is not provided in the available source set used for this analysis. For a mature HMB drug category, branded volume generally trends with branded-to-generic substitution after generic entry and formulary pressure.
Category context: heavy menstrual bleeding treatment demand
Demand for HMB therapies is influenced by:
- Incidence of HMB in reproductive-age women
- Prescribing preference for oral agents before procedural pathways
- Growth in women’s health and outpatient gynecology visits
- Shift toward non-surgical management when appropriate
Market projection: what revenue range is plausible for Lysteda over the next 5 years?
A quantified forecast range cannot be produced from the available sources used here because the analysis run does not include:
- Current-year revenues (US and international)
- Paid prescriptions or TRx time series
- Net price trend assumptions and share of branded product
- Country-by-country penetration metrics
Given the product is mature and faces broad generic competition, the base-case market outcome for Lysteda generally follows branded erosion dynamics: flat-to-declining branded revenue with periodic stabilization where contracting insulates share.
What patent estate and litigation risks affect Lysteda in the US?
No current Lysteda patent litigation dataset is included in the provided source set for this analysis. Without case-level filings, Orange Book patent-by-patent mapping, and the status of any Paragraph IV challenges or settlements, the litigation impact cannot be specified.
Which patent types matter most for Lysteda market protection?
For established tablet products, the relevant risk channels typically include:
- Method-of-treatment claims tied to HMB management
- Formulation or dosing regimen claims
- Process/manufacturing claims
- Second-generation salts/polymorphs (less common for tranexamic acid tablets unless specifically developed)
How does Lysteda compare with other oral options for heavy menstrual bleeding (mechanism, positioning, and payer preference)?
Lysteda’s positioning is anchored in oral tranexamic acid use for cyclic HMB. Competitors include:
- Other medical management options used in HMB (hormonal therapies, other non-hormonal oral agents depending on availability in a given market)
- Procedural pathways in parallel (endometrial ablation, hysterectomy) that compete indirectly via treatment switching
Mechanism
Tranexamic acid is an antifibrinolytic. Clinical use targets reduction in menstrual blood loss during menses.
Payer preference
Payer coverage often depends on:
- Net cost versus equivalents
- Prior authorization requirements
- Evidence thresholds and formulary tiers
What generic entry risks exist for Lysteda, and how do ANDA timelines typically translate into launch scenarios?
Generic entry has already occurred in practice in the US market. The ongoing risk for branded outcomes is not “first generic launch” but incremental substitution as additional ANDAs mature, pricing drops, and contracting tightens.
How to interpret the launch playbook for a mature generic market
- Each new ANDA can compress net pricing.
- Brand share typically depends on rebate competitiveness and formulary retention.
- Pharmacy channel behavior shifts toward lowest net cost, especially for non-preferred products.
Key takeaways
- Lysteda’s clinical program activity visible in the available source set is limited to non-registrational updates; no new phase-advancing, label-expanding trials are identified for tranexamic acid tablets.
- The competitive environment remains dominated by generic tranexamic acid for HMB in the US, with branded performance driven by contracting and net pricing rather than clinical differentiation.
- Current-year market size, branded share, and a 5-year revenue projection cannot be quantified from the provided sources in this analysis run.
- Patent- and litigation-driven protection status is not mapped here because the underlying Orange Book patent list, expiration dates, and case records are not included in the available source set.
FAQs
- What is the current US indication and dosing pattern for Lysteda in heavy menstrual bleeding?
- How does tranexamic acid’s antifibrinolytic mechanism affect bleeding outcomes versus hormonal therapies for HMB?
- Which formulary and rebate levers most influence Lysteda’s branded prescriptions versus generic tranexamic acid?
- What are the main safety considerations for tranexamic acid in women with HMB (thromboembolic risk, contraindications)?
- How do additional ANDA approvals typically impact branded revenue for mature oral small-molecule drugs like Lysteda?
References (APA)
- FDA. (n.d.). Product label information for Lysteda (tranexamic acid). U.S. Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA. (n.d.). Assessment history and product information for tranexamic acid products indicated for heavy menstrual bleeding. European Medicines Agency.
